CLLS

Cellectis SA is a clinical-stage biotechnology firm headquartered in Paris, France, specializing in the development of innovative immuno-oncology therapies utilizing its proprietary gene-editing platform. By leveraging its cutting-edge technology, the company creates T cell therapies that incorporate chimeric antigen receptors (CARs) to effectively target and eliminate cancer cells. With a diverse pipeline of candidates at various clinical development stages and strategic partnerships, Cellectis is strategically positioned to transform cancer treatment, addressing critical unmet medical needs and aiming to improve patient outcomes significantly.